Bangalore : AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full-year results for the financial year (FY) ended 31 March 2026. The Company maintained strong momentum during the year and delivered an 33% year-on-year growth in total revenue, reflecting sustained performance across its therapy areas and continued progress in bringing innovative medicines to patients in India.
Financial Performance Summary: (Value in INR Mn)
| Summary | Q4 (Jan- Mar ’26) | Full FY Apr ’25- Mar ’26 |
| Total revenue from Operations | 5,786.1 | 22,755.8 |
| Profit before exceptional item and tax | 592.2 | 2,574.5 |
| Profit after exceptional item and tax | 448.8 | 1,875.2 |
| Summary | Full FY Apr ’25- Mar ’26 | |
| TA-wise performance | Oncology | 16,100.9 |
| Biopharmaceuticals (CVRM, R&I and V&I) | 5,243.2 | |
| Rare Disease | 214.6 | |
During FY 2025-26, AstraZeneca India recorded total revenue from operations of INR 22,755.8 Mn, supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease. The year was also marked by 11 new regulatory approvals for medicines and indications, underscoring the Company’s commitment to scientific innovation, bringing them to the country at an accelerated pace and its focus on addressing unmet patient needs across India.
Bhavana Agrawal, Chief Financial Officer & Director of the Company, said: “FY 2025-26 was a year of strong and consistent growth for AstraZeneca India, underpinned by the resilience of our business, the strength of our science-led portfolio, and disciplined execution across the organisation. Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet.”
Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca India, added: “At AstraZeneca, science is at the heart of everything we do. Our FY 2025-26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India. With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation.”
Key milestones: During FY ’25-26, the Company achieved several important regulatory approvals from CDSCO and business milestones that strengthened its portfolio and expanded patient access to innovative therapies in India.
- Durvalumab – endometrial cancer: Durvalumab in combination with carboplatin and paclitaxel is now indicated for first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy; followed by maintenance treatment with Durvalumab in combination with Olaparib in endometrial cancer that is mismatch repair-proficient (pMMR).
- Durvalumab – endometrial cancer: Durvalumab in combination with carboplatin and paclitaxel is now indicated for first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy; followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR).
- Durvalumab – muscle invasive bladder cancer (MIBC): Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Durvalumab as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
- Osimertinib – NSCLC: Osimertinib is indicated in combination with Pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
- Trastuzumab deruxtecan – HER 2 low and HER 2 ultralow breast cancer: Trastuzumab deruxtecan is indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2- low (IHC 1+ or IHC 2+/ISH-) or HER2- ultralow (IHC0 with membrane staining) BC, who have received at least one endocrine therapy in metastatic setting.
- Trastuzumab deruxtecan – Other Unresectable or Metastatic Solid Tumours: Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.
- Osimertinib – NSCLC (stage III, monotherapy): Osimertinib as monotherapy is indicated for
the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.
- Benralizumab – EGPA: Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
- Durvalumab – Gastric Cancer: Durvalumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent Durvalumab, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
- Durvalumab – Liver Cancer: Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior systemic therapy.
- Datopotamab Deruxtecan – Breast Cancer: Datopotamab Deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Recognitions:
- Pharma Company of the Year at ET RePharma Awards
- Medical Excellence Award for Rare Disease at OPPI India
- Recognised as Top Employer India 2025
- Marketing Excellence Award for Hyperkalaemia & Kidney Care, Biopharmaceuticals at OPPI India
- OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials.
- 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials.
- ET HRWorld EX Awards 2025: AstraZeneca Pharma India awarded for Exceptional Employee Experience (Large Scale), recognising our progress in I&D.
- Excellence in Precision Biopharma Solutions at the VOH National Healthcare Awards 2025.